New Chemotherapy Strategy Emerges in Ovarian Cancer

Anita T. Shaffer @Shaffer1
Published: Monday, Sep 24, 2012
Dr. Jonathan S. Berek

Jonathan S. Berek, MD, MMS

Professor and Director, Women’s Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

A study evaluating first-line chemotherapy dosing strategies for treating patients with advanced epithelial ovarian cancer has delivered practice-changing findings, and ongoing trials are likely to provide further clarity on the comparative benefits of routes of administration, according to Jonathan S. Berek, MD, MMS.

Key Statistics in JGOG 3016 Trial, at 6.4 Years’ Follow-Up1

Treatment Patients (No) Median PFS Median OS
Dose-Dense 312 28.2 mo Not reached
Conventional 319 17.5 mo 62.2 mo
P value   .0037 .039

PFS indicates progression-free survival; OS, overall survival.

A subgroup analysis indicated that patients with clear-cell and mucinous carcinomas, who made up 15% to 17% of patients, did not show a statistically significant advantage with either treatment strategy. More than 80% of the patients in each arm had serous adenocarcinomas and other types.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.